|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.21 USD | -9.02% |
|
-11.68% | -2.42% |
| May. 09 | Transcript : Akebia Therapeutics, Inc., Q1 2024 Earnings Call, May 09, 2024 | |
| May. 09 | Earnings Flash (AKBA) AKEBIA THERAPEUTICS Reports Q1 Revenue $32.6M | MT |
Akebia Therapeutics, Inc. affirmed revenue guidance for the year 2022. For the year, the company affirm 2022 net product revenue guidance for Auryxia of $170 million - $175 million.
| 1st Jan change | Capi. | |
|---|---|---|
| -2.42% | 253M | |
| +3.91% | 109B | |
| +10.87% | 105B | |
| +1.28% | 22.25B | |
| -13.14% | 22.09B | |
| -7.05% | 18.68B | |
| -38.36% | 17.58B | |
| -10.66% | 16.85B | |
| +3.75% | 13.76B | |
| +36.70% | 12.46B |
AKEBIA THERAPEUTICS, INC. 